Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 6, 1998, Pages 1355-1360

  Climo, Michael W ^a,c   Patron, Roberto L ^a   Goldstein, Beth P ^b   Archer, Gordon L ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b AMBI Inc   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMBICIL L; LYSOSTAPHIN; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA VALVE; ARTICLE; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0031805819     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.6.1355     Document Type: Article

References (45)

1. Bayer, A. S., and K. Lam. 1985. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J. Infect. Dis. 151:157-165.
2. Boyce, J. M., and A. A. Medeiros. 1997. Clinical isolates of methicillin-resistant Staphylococcus aureus from the United States with subpopulations of cells with reduced susceptibility to vancomycin, abstr. LB-15, p. 6. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
3. Bramley, A. J., and R. Foster. 1990. Effects of lysostaphin on Staphylococcus aureus infections of the mouse mammary gland. Res. Vet. Sci. 49:120-121.
4. Centers for Disease Control and Prevention. 1997. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997. Morbid. Mortal. Weekly Rep. 46:813-815.
5. Chambers, H. F. 1995. In vitro and in vivo antistaphylococcal activities of L-695,256, a carbapenem with high affinity for the penicillin-binding protein PBP 2a. Antimicrob. Agents Chemother. 39:462-466.
6. Chambers, H. F., C. J. Hackbarth, T. A. Drake, M. G. Rusnak, and M. A. Sande. 1984. Endocarditis due to methicillin-resistant Staphylococcus aureus in rabbits: expression of resistance to β-lactam antibiotics in vivo and in vitro. J. Infect. Dis. 149:894-903.
7. Chambers, H. F., M. Kartalija, and M. Sande. 1995. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J. Infect. Dis. 171:897-902.
8. Chambers, H. F., and S. Kennedy. 1990. Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis. Antimicrob. Agents Chemother. 34:510-514.
9. Chambers, H. F., and M. H. Miller. 1987. Emergence of resistance to cephalothin and gentamicin during combination therapy for methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J. Infect. Dis. 155: 581-585.
10. Chambers, H. F., and M. A. Sande. 1984. Teicoplanin versus nafcillin and vancomycin in the treatment of experimental endocarditis caused by methicillin-susceptible or -resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 26:61-64.
11. Chambers, H. F., M. Sachdeva, and S. Kennedy. 1990. Binding affinity for penicillin-binding protein 2a correlates with in vivo activity of β-lactam antibiotics against methicillin-resistant Staphylococcus aureus. J. Infect. Dis. 162:705-710.
12. Clark, N. C., R. C. Cooksey, B. C. Hill, J. M. Swenson, and F. C. Tenover. 1993. Characterization of glycopeptide-resistant enterococci from U.S. hospitals. Antimicrob. Agents Chemother. 37:2311-2317.
13. Climo, M. W., S. M. Markowitz, D. S. Williams, C. G. Hale-Cooper, and G. L. Archer. 1997. Comparison of in-vitro and in-vivo efficacy of FK037, vancomycin, imipenem and nafcillin against staphylococcal species. J. Antimicrob. Chemother. 40:59-66.
14. De Gorgolas, M., P. Aviles, C. Verdejo, and M. L. Fernandez Guerrero. 1995. Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimehoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis. Antimicrob. Agents Chemother. 39:953-957.
15. Dixon, R. E., J. S. Goodman, and M. G. Koenig. 1968. Lysostaphin: an enzymatic approach to staphylococcal disease. III. Combined lysostaphin-methicillin therapy of established staphylococcal abscesses in mice. Yale J. Biol. Med. 41:62-68.
16. Fantin, B., R. Leclercq, J. Duval, and C. Carbon. 1993. Fusidic acid alone or in combination with vancomycin for therapy of experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 37:2466-2469.
17. Fantin, B., R. Leclercq, Y. Merle, L. Saint-Julien, C. Veyrat, J. Duval, and C. Carbon. 1995. Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus. Antimicrob. Agents Chemother. 39:400-405.
18. Fantin, B., R. Leclercq, M. Ottaviani, J.-M. Vallois, B. Maziere, J. Duval, J.-J. Pocidalo, and C. Carbon. 1994. In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis. Antimicrob. Agents Chemother. 38:432-437.
19. Fantin, B., J. Pierre, N. Castela-Papin, L. Saint-Julien, H. Drugeon, R. Farinotti, and C. Carbon. 1996. Importance of penicillinase production for activity of penicillin alone or in combination with sulbactam in experimental endocarditis due to methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 40:1219-1224.
20. Gilbert, M., J. A. Boscia, W. D. Kobasa, and D. Kaye. 1986. Enoxacin compared with vancomycin for the treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 29:461-463.
21. Goldberg, L. M., J. M. DeFranco, C. Watanakunakorn, and M. Hamburger. 1967. Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin, p. 45-53. Antimicrob. Agents Chemother. 1966.
22. Harris, R. L., A. W. Nunnery, and H. D. Riley, Jr. 1967. Effects of lysostaphin on staphylococcal carriage in infants and children. Antimicrob. Agents Chemother. 7:110-112.
23. Harrison, E. F., and C. B. Cropp. 1967. Therapeutic activity of lysostaphin in experimental staphylococcal infections. Can. J. Microbiol. 13:93-97.
24. Harrison, E. F., and W. A. Zygmunt. 1967. Lysostaphin in experimental renal infections. J. Bacteriol. 93:520-524.
25. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguru, and F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J. Antimicrob. Chemother. 40:135-146.
26. Kaatz, G. W., S. L. Barriere, D. R. Schaberg, and R. Fekety. 1987. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 31:527-530.
27. Kaatz, G. W., S. M. Seo, S. L. Barriere, L. M. Albrecht, and M. J. Rybak. 1989. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 33:519-521.
28. Kaatz, G. W., S. M. Seo, V. N. Reddy, E. M. Bailey, and M. J. Rybak. 1990. Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditis. Antimicrob. Agents Chemother. 34:2081-2085.
29. Levine, D. P., B. S. Fromm, and B. R. Reddy. 1991. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann. Intern. Med. 115:674-680.
30. Martin, R. R., and A. White. 1967. The selective activity of lysostaphin in vivo. J. Lab. Clin. Med. 70:1-8.
31. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: Approved standard M7-A4. 4th edition. National Committee for Clinical Laboratory Standards, Villanova, Pa.
32. Nicolau, D. P., C. D. Freeman, C. H. Nightingale, C. J. Coe, and R. Quintiliani. 1994. Minocycline versus vancomycin for treatment of experimental endocarditis caused by oxacillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 38:1515-1518.
33. Oldham, E. R., and M. J. Daley. 1991. Lysostaphin: use of a recombinant bactericidal enzyme as a mastitis therapeutic. J. Dairy Sci. 74:4175-4182.
34. Perdikaris, G., H. Giamarellou, A. Pefanis, I. Donta, and P. Karayiannakos. 1995. Vancomycin or vancomycin plus netilmicin for methicillin- and gentamicin-resistant Staphylococcus aureus aortic valve experimental endocarditis. Antimicrob. Agents Chemother. 39:2289-2294.
35. Perlman, B. B., and L. R. Freedman. 1971. Experimental endocarditis. II. Staphylococcal infection of the aortic valve following placement of a polyethylene catheter in the left side of the heart. Yale J. Biol. Med. 44:206-213.
36. Quickel, K. E., Jr., R. Selden, J. R. Caldwell, N. F. Nora, and W. Schaffner. 1971. Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus. Appl. Microbiol. 22:446-450.
37. Recsei, P. A. June 1990. U.S. patent 4,931,390.
38. Robinson-Dunn, B., G. Jennings, J. Mitchell, M. Ionescu, D. Farnaz, S. Donabedian, M. B. Perri, L. A. Thal, J. Sunstrum, J. W. Chow, T. Smith, and M. J. Zervos. 1997. Characterization of a unique isolate of vancomycin-intermediate Staphylococcus aureus. abstr. LB-14, p. 6. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Washington, D.C.
39. Schaffner, W., M. A. Melly, J. H. Hash, and M. G. Koenig. 1967. Lysostaphin: an enzymatic approach to staphylococcal disease. I. In vitro studies. Yale J. Biol. Med. 39:215-229.
40. Schaffner, W., M. A. Melly, and M. G. Koenig. 1967. Lysostaphin: an enzymatic approach to staphylococcal disease. II. In vivo studies. Yale J. Biol. Med. 39:230-244.
41. Schuhardt, V. T., and C. A. Schindler. 1964. Lysostaphin therapy in mice infected with Staphylococcus aureus. J. Bacteriol. 88:815-816.
42. Small, P. M., and H. F. Chambers. 1990. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. Antimicrob. Agents Chemother. 34:1227-1231.
43. Smith, T. L., M. Pearson, K. Wilcox, B. Robinson-Dunn, B. Hill, M. Lancaster, G. Rodgers, C. Ruble, E. Flegel, S. McCallister, J. M. Miller, H. Ellis, C. Campbell, and W. R. Jarvis. 1997. Staphylococcus aureus with reduced susceptibility to vancomycin. United States, 1997, abstr. LB-16, p. 6. In Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
44. Stark, F. R., C. Thornsvard, E. P. Flannery, and M. S. Artenstein. 1974. Systemic lysostaphin in man. Apparent antimicrobial activity in a neutropenic patient. N. Engl. J. Med. 291:239-240.
45. Zygmunt, W., and P. A. Tavormina. 1972. Lysostaphin: model for a specific enzymatic approach to infectious disease. Prog. Drug Res. 16:309-333.